ArticleApplied biochemistry and biotechnology2026
Multifunctional Ag/MgO Nanocomposite from Marine Bacterium Bacillus tequilensis MYG163 EPS Triggers Metalloptosis in HepG2 Cells Through p53-Mediated DNA Damage and Caspase-3 Activation.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-targeted pyrazole scaffolds: synthesis, mechanistic insights, and therapeutic potential in anticancer, antioxidant, and anti-inflammatory applications.The Libyan journal of medicine · 2026Article
- BiogenicRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contemporary cancer therapies encounter fundamental obstacles such as resistance development, systemic toxicity thresholds, inadequate tumor discrimination, and restricted treatment efficacy ranges. To synthesize biogenic Ag/MgO nanocomposite using marine bacterium Bacillus tequilensis MYG163 exopolysaccharide and evaluate its multifunctional therapeutic properties. Ag/MgO nanocomposite was synthesized via bacterial EPS-mediated biogenic route and characterized by UV-Vis, FT-IR, TEM, XRD, EDX, DLS, and zeta potential. Hemocompatibility, antioxidant capacity (DPPH, ABTS•+), anti-inflammatory activity (COX-1/COX-2 inhibition), and cytotoxicity against WI38 fibroblasts and four cancer cell lines, HepG2 (hepatocellular carcinoma), MCF-7 (breast cancer), HeLa (cervical cancer), and PC-3 (prostate cancer) were evaluated. Apoptotic mechanisms were examined through qRT-PCR, comet assay, diphenylamine assay, and flow cytometry. Biogenic synthesis using B. tequilensis MYG163 EPS yielded spherical Ag/MgO nanocomposite (10–50 nm), negative surface charge (-26.8 mV), hydrodynamic size of 56.8 nm containing 29.6 wt% silver and 8.8 wt% magnesium with face-centered cubic silver reflections and cubic periclase MgO structure. XRD confirmed crystalline phases at 38.04°, 43.32°, 62.65° (Ag) and 59.27°, 75.05° (MgO). Hemolysis remained ≤ 1.6% at 1000 µg/mL. Antioxidant IC₅₀: 22.22 µg/mL (DPPH), 17.38 µg/mL (ABTS•+). Anti-inflammatory IC₅₀: 110.67 µg/mL (COX-1), 167.47 µg/mL (COX-2). Cancer cell IC₅₀ ranged 61.12–149.51 µg/mL vs. 369.53 µg/mL (WI38). HepG2 treatment triggered p53 (378%), p21 (487%), Bax (297%), Caspase-3 (654%) upregulation, Bcl-2 (64%) downregulation, DNA damage (73% increase), S-phase arrest (42.80%), and G2/M block (8.35%). Bacterial EPS enables single-step synthesis of biocompatible Ag/MgO nanocomposite with integrated antioxidant, anti-inflammatory, and cancer-selective apoptotic properties, offering potential for targeted therapy development.
Indexed as
Identifiers
41653263What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.